<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04002154</url>
  </required_header>
  <id_info>
    <org_study_id>PHPC-201501</org_study_id>
    <nct_id>NCT04002154</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV</brief_title>
  <acronym>PALOMA</acronym>
  <official_title>Ensayo clínico, Aleatorizado, Abierto, de Grupos Paralelos y Con Grupo Control, Para Explorar la Eficacia Del Gel PAPILOCARE en la reparación de la Mucosa cérvico-vaginal Con Lesiones Causadas Por VPH (Ensayo Clínico PALOMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procare Health Iberia S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adknoma Health Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Procare Health Iberia S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to&#xD;
      evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal&#xD;
      mucosa with lesions caused by HPV. All the patients included in the study will be Randomized&#xD;
      (1:1:1).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to&#xD;
      evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal&#xD;
      mucosa with lesions caused by HPV. All the patients included in the study will be Randomized&#xD;
      (1:1:1) to Arm A (Papilocare schedule A), Arm B (Papilocare schedule B) and Arm C (usual&#xD;
      clinical practice -without treatment-). Selection period of 1 month, followed by&#xD;
      randomization and 6 months of treatment followed by a period of another 6 months without&#xD;
      treatment. Patients will visit the site into a total of 5 visits throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 19, 2015</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Repairment of the cervico-vaginal mucosa in positive HPV women measured by normal cytology with concordant colposcopy image</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the repairment of the cervico-vaginal mucosa in positive HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image, 6 months after the start of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Repairment of the cervico-vaginal mucosa in positive HPV women measured by normal cytology with concordant colposcopy image</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Evaluate the repairment of the cervico-vaginal mucosa in positive HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image at 3 and 12 months after the start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reeptielization of the cervico-vaginal mucosa measured by a likert scale.</measure>
    <time_frame>3,6 and 12 months</time_frame>
    <description>Evaluate the reeptielization of the cervico-vaginal mucosa months after the start of treatment measured by likert scale, using a total of 5 points (1 is severe ectopy + external bleeding, 2 is severe or extensive ectopy:&gt; 50%, 3 is moderate ectopy: 25-50%, 4 is mild ectopy: &lt;25% and 5 is no ectopy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal health status measured by Bachmann Index.</measure>
    <time_frame>3,6 and 12 months</time_frame>
    <description>Evaluate vaginal health status from the start of treatment measured by Bachmann Index, it contains 5 domains that evaluate elasticity, type of secretion, pH, epithelial integrity and moisture, scoring each of them from 1 to 5, considering the maximum score as the best vaginal health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of papilocare gel use measured by likert scale.</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Evaluate the satisfaction of papilocare gel use by the patients after the start of treatment measured by likert scale, it is a single-item instrument that assesses the degree of satisfaction experienced by the patient with a graded response of 7 values ranging from 1 (satisfied) to 7 (not satisfied at all).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic compliance</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Evaluate the therapeutic compliance from the start of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Human Papilloma Virus Infection</condition>
  <condition>Human Papilloma Virus</condition>
  <condition>Cervix Lesion</condition>
  <arm_group>
    <arm_group_label>A - papilocare alternative days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - papilocare semiintensive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Arm C: usual clinical practice: no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Papilocare vaginal gel</intervention_name>
    <description>Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution</description>
    <arm_group_label>A - papilocare alternative days</arm_group_label>
    <arm_group_label>B - papilocare semiintensive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Woman between the ages of 30 and 65 (both included).&#xD;
&#xD;
          2. Able to read and understand the Patient Information Sheet and the Informed Consent&#xD;
             form.&#xD;
&#xD;
          3. Accept participation in the study and sign the Informed Consent form.&#xD;
&#xD;
          4. Cytological result of ASC-US or LSIL or AG-US, with matching colposcopic image,&#xD;
             maximum 3 months before the screening visit.&#xD;
&#xD;
          5. Positive HPV by PCR performed at the screening visit (or positive available at most 3&#xD;
             months prior to the baseline visit).&#xD;
&#xD;
          6. Is capable, at the discretion of the investigator, of complying with the requirements&#xD;
             of the study protocol and without impediments to follow the instructions and&#xD;
             evaluations throughout it.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically relevant immune system alterations, or any other autoimmune disease or in&#xD;
             treatment with immunosuppressants.&#xD;
&#xD;
          2. Non-diagnosed abnormal genital hemorrhage (during the 6 months prior to the screening&#xD;
             visit).&#xD;
&#xD;
          3. To had been vaccinated against HPV.&#xD;
&#xD;
          4. Other symptomatic vulvovaginal infections.&#xD;
&#xD;
          5. Surgical cervical excision in the last year or total hysterectomy.&#xD;
&#xD;
          6. Previous history of gynecological cancer.&#xD;
&#xD;
          7. Participation in any other clinical trial at present or in the 4 weeks prior to the&#xD;
             inclusion of the study.&#xD;
&#xD;
          8. Any planned surgery that prevents the correct compliance with the protocol.&#xD;
&#xD;
          9. Use of vaginal contraceptives or other vaginal hormonal treatments.&#xD;
&#xD;
         10. Contraindications for Papilocare gel use or known allergies to any of its components.&#xD;
&#xD;
         11. Women of childbearing age who do not use effective contraceptive methods, pregnant&#xD;
             women, with suspicion of pregnancy or woman who are breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Cortés Bordoy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital os Palma de Mallorca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Diatros - TEKNON</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women´s Health Institute</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinete Médico Velázquez</name>
      <address>
        <city>Madrid</city>
        <zip>28001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Palacios de Salud y Medicina de la Mujer</name>
      <address>
        <city>Madrid</city>
        <zip>41720</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>It must be discussed with investigators team</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

